Recent News

• 05.27.2025 - Altamira Therapeutics Announces Collaboration on Circular RNA Delivery
• 04.30.2025 - Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
• 04.30.2025 - Altamira Therapeutics Provides Business Update, Reports Full Year 2024 Financial Results
• 04.30.2025 - Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call
• 04.30.2025 - Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call
• 04.25.2025 - Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025
• 04.25.2025 - Altamira Therapeutics to Host Full Year 2024 Financial Results and Business Update Call on April 30, 2025
• 03.07.2025 - Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent
• 03.07.2025 - Altamira Announces Notice of Allowance from USPTO for Bentrio Nasal Spray Patent
• 01.22.2025 - Altamira Therapeutics Announces Collaboration on Radiopharmaceutical Targeting Strategies

Recent Filings

• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.09.2025 - EX-99.1 EX-99.1
• 05.06.2025 - SCHEDULE 13D/A General Statement of Acquisition of Beneficial Ownership
• 04.30.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 04.30.2025 - EX-99.1 EX-99.1
• 04.30.2025 - 20-F Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
• 04.04.2025 - S-8 Securities to be offered to employees in employee benefit plans
• 03.10.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors